MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Uterine Cervical Neoplasms|Endometrial Neoplasms|Squamous Cell Carcinoma of Head and Neck|Gallbladder Neoplasms|Cholangiocarcinoma|Esophageal Neoplasms|Triple Negative Breast Neoplasms|Hepatocellular Carcinoma|Urinary Bladder Neoplasms|Ovarian Neoplasms|Stomach Neoplasms
Interventions: BIOLOGICAL: Pembrolizumab/Vibostolimab Co-Formulation|BIOLOGICAL: Pembrolizumab|DRUG: Lenvatinib|DRUG: 5-Fluorouracil|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Bevacizumab|DRUG: Capecitabine|DRUG: Oxaliplatin
Sponsor: Merck Sharp & Dohme LLC